These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 34959361)

  • 1. Eutectic Formation of Naproxen with Some Dicarboxylic Acids.
    Kim D; Jang S; Kim IW
    Pharmaceutics; 2021 Dec; 13(12):. PubMed ID: 34959361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced Dissolution of Naproxen by Combining Cocrystallization and Eutectic Formation.
    Kim H; Jang S; Kim IW
    Pharmaceutics; 2021 Apr; 13(5):. PubMed ID: 33923065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Binary Mixtures of Some Active Pharmaceutical Ingredients with Fatty Alcohols-The Criteria of Successful Eutectic Formation and Dissolution Improvement.
    Jin S; Jang J; Lee S; Kim IW
    Pharmaceutics; 2020 Nov; 12(11):. PubMed ID: 33207728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reactive Melt Extrusion To Improve the Dissolution Performance and Physical Stability of Naproxen Amorphous Solid Dispersions.
    Liu X; Zhou L; Zhang F
    Mol Pharm; 2017 Mar; 14(3):658-673. PubMed ID: 28135108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levetiracetam+nonsteroidal anti-inflammatory drug binary systems: A contribution to the development of new solid dosage forms.
    Machado SMT; Castro RAE; Maria TMR; Canotilho J; Eusébio MES
    Int J Pharm; 2017 Nov; 533(1):1-13. PubMed ID: 28893584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Solid-Liquid Equilibrium in Co-Amorphous Systems: Experiment and Prediction.
    Zemánková A; Hassouna F; Klajmon M; Fulem M
    Molecules; 2023 Mar; 28(6):. PubMed ID: 36985463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancement of dissolution rate through eutectic mixture and solid solution of posaconazole and benznidazole.
    Figueirêdo CBM; Nadvorny D; de Medeiros Vieira ACQ; Soares Sobrinho JL; Rolim Neto PJ; Lee PI; de La Roca Soares MF
    Int J Pharm; 2017 Jun; 525(1):32-42. PubMed ID: 28412452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microfluidic Particle Engineering of Hydrophobic Drug with Eudragit E100─Bridging the Amorphous and Crystalline Gap.
    Shikha S; Lee YW; Doyle PS; Khan SA
    Mol Pharm; 2022 Nov; 19(11):4345-4356. PubMed ID: 36268657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preparation, characterization, and evaluation of celecoxib eutectic mixtures with adipic acid/saccharin for improvement of wettability and dissolution rate.
    Hyun SM; Lee BJ; Abuzar SM; Lee S; Joo Y; Hong SH; Kang H; Kwon KA; Velaga S; Hwang SJ
    Int J Pharm; 2019 Jan; 554():61-71. PubMed ID: 30347274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determination of Stable Co-Amorphous Drug-Drug Ratios from the Eutectic Behavior of Crystalline Physical Mixtures.
    Kissi EO; Khorami K; Rades T
    Pharmaceutics; 2019 Nov; 11(12):. PubMed ID: 31771255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contribution of Crystal Lattice Energy on the Dissolution Behavior of Eutectic Solid Dispersions.
    Chaturvedi K; Shah HS; Nahar K; Dave R; Morris KR
    ACS Omega; 2020 May; 5(17):9690-9701. PubMed ID: 32391455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Controlled release of pharmaceutical agents using eutectic modified gelatin.
    Qu W; Qader IB; Abbott AP
    Drug Deliv Transl Res; 2022 May; 12(5):1187-1194. PubMed ID: 33966177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors affecting the formation of eutectic solid dispersions and their dissolution behavior.
    Vippagunta SR; Wang Z; Hornung S; Krill SL
    J Pharm Sci; 2007 Feb; 96(2):294-304. PubMed ID: 17051588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Properties of rapidly dissolving eutectic mixtures of poly(ethylene glycol) and fenofibrate: the eutectic microstructure.
    Law D; Wang W; Schmitt EA; Qiu Y; Krill SL; Fort JJ
    J Pharm Sci; 2003 Mar; 92(3):505-15. PubMed ID: 12587112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dissolution enhancement of active pharmaceutical ingredients by therapeutic deep eutectic systems.
    Aroso IM; Silva JC; Mano F; Ferreira AS; Dionísio M; Sá-Nogueira I; Barreiros S; Reis RL; Paiva A; Duarte AR
    Eur J Pharm Biopharm; 2016 Jan; 98():57-66. PubMed ID: 26586342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of ezetimibe eutectic with improved biopharmaceutical and mechanical properties to design an optimized oral solid dosage formulation.
    Roy P; Kumari N; Pandey N; Gour A; Raj A; Srividya B; Nandi U; Ghosh A
    Pharm Dev Technol; 2022 Dec; 27(10):989-998. PubMed ID: 36322702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preparation and characterization of glimepiride eutectic mixture with l-arginine for improvement of dissolution rate.
    Park H; Seo HJ; Ha ES; Hong SH; Kim JS; Kim MS; Hwang SJ
    Int J Pharm; 2020 May; 581():119288. PubMed ID: 32243966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Solids Turn into Liquids-Liquid Eutectic Systems of Pharmaceutics to Improve Drug Solubility.
    Sarraguça MC; Ribeiro PRS; Nunes C; Seabra CL
    Pharmaceuticals (Basel); 2022 Feb; 15(3):. PubMed ID: 35337077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eutectic Mixture Formation and Relaxation Dynamics of Coamorphous Mixtures of Two Benzodiazepine Drugs.
    Valenti S; Cazorla C; Romanini M; Tamarit JL; Macovez R
    Pharmaceutics; 2023 Jan; 15(1):. PubMed ID: 36678825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selecting Excipients Forming Therapeutic Deep Eutectic Systems-A Mechanistic Approach.
    Wolbert F; Brandenbusch C; Sadowski G
    Mol Pharm; 2019 Jul; 16(7):3091-3099. PubMed ID: 31095911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.